News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opexa Pharmaceuticals, Inc. Executes Strategic Service Agreement with the American Red Cross


5/17/2011 10:29:22 AM

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has executed an agreement with the American Red Cross to provide blood procurement services to support Opexa’s upcoming Phase III study of Tovaxin in patients with Relapsing-Remitting MS.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES